SunTrust Robinson Humphrey Initiates Coverage On Fate Therapeutics with Buy Rating, Announces $25 Price Target

SunTrust Robinson Humphrey initiates coverage on Fate Therapeutics (NASDAQ:FATE) with a Buy rating and a $25 price target.

Benzinga · 11/12/2019 11:25

SunTrust Robinson Humphrey initiates coverage on Fate Therapeutics (NASDAQ:FATE) with a Buy rating and a $25 price target.